« Back
Home /
CFT8634

CFT8634

Item no.	HY-145925B-5mg
Manufacturer	MedChem Express
CASRN	2704617-96-7
Amount	5 mg
Quantity options	10 mg 1 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	98.10
Citations	[1]Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793.\|[2]Jackson, et al. "Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers." Cancer Research 82.12_Supplement (2022): ND09-ND09.\|[3]Poling, et al. "CFT8634, a clinical stage BRD9 Bi DAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide." Blood 142 (2023): 6594.\|[4]Poling, et al. "CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone." Cancer Research 84.6_Supplement (2024): 6046-6046.
Smiles	CC(C(C1=CC(OC)=C(C(OC)=C1)CN2CC(F)([C@@H](N3CCN(C4=C(C=C(C=C4)N[C@@H]5C(NC(CC5)=O)=O)F)CC3)CC2)F)=CN6C)=C(C)C6=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Epigenetic Reader Domain; PROTACs
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	710.79
Product Description	CFT8634 is an orally bioavailable PROTAC BRD9 targeted degrader based on the E3 ubiquitin ligase CRBN mechanism. CFT8634 can be used for the study of synovial sarcoma and SMARCB1-deficient solid tumors (Pink: BRD9 ligand (HY-169988); Blue: E3 ligase ligand (HY-169989); Black: linker (HY-169991). CFT8634 is a heterobifunctional molecule that binds to BRD9 at one end and recruits CRBN at the other end, which can inhibit the growth of tumor cells that depend on BRD9. CFT8634 can be used for the study of SMARCB1-related cancers (such as synovial sarcoma and malignant rhabdoid tumor)[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics; PROTAC
Isoform	Cereblon
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-145925B-5mg-safety-datasheet.pdf